These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

222 related items for PubMed ID: 35985100

  • 1. Predicting drug-drug interactions with physiologically based pharmacokinetic/pharmacodynamic modelling and optimal dosing of apixaban and rivaroxaban with dronedarone co-administration.
    Wen HN, He QF, Xiang XQ, Jiao Z, Yu JG.
    Thromb Res; 2022 Oct; 218():24-34. PubMed ID: 35985100
    [Abstract] [Full Text] [Related]

  • 2. Development and verification of a physiologically based pharmacokinetic model of dronedarone and its active metabolite N-desbutyldronedarone: Application to prospective simulation of complex drug-drug interaction with rivaroxaban.
    Leow JWH, Ang XJ, Chan ECY.
    Br J Clin Pharmacol; 2023 Jun; 89(6):1873-1890. PubMed ID: 36683488
    [Abstract] [Full Text] [Related]

  • 3. Physiologically-Based Pharmacokinetic Modeling for the Prediction of a Drug-Drug Interaction of Combined Effects on P-glycoprotein and Cytochrome P450 3A.
    Otsuka Y, Choules MP, Bonate PL, Komatsu K.
    CPT Pharmacometrics Syst Pharmacol; 2020 Nov; 9(11):659-669. PubMed ID: 33030266
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetic and pharmacodynamic drug interactions with new oral anticoagulants: what do they mean for patients with atrial fibrillation?
    Hellwig T, Gulseth M.
    Ann Pharmacother; 2013 Nov; 47(11):1478-87. PubMed ID: 24259602
    [Abstract] [Full Text] [Related]

  • 5. The real world use of combined P-glycoprotein and moderate CYP3A4 inhibitors with rivaroxaban or apixaban increases bleeding.
    Hanigan S, Das J, Pogue K, Barnes GD, Dorsch MP.
    J Thromb Thrombolysis; 2020 May; 49(4):636-643. PubMed ID: 31925665
    [Abstract] [Full Text] [Related]

  • 6. Physiologically-based pharmacokinetic modeling to predict drug-drug interaction of enzalutamide with combined P-gp and CYP3A substrates.
    Otsuka Y, Poondru S, Bonate PL, Rose RH, Jamei M, Ushigome F, Minematsu T.
    J Pharmacokinet Pharmacodyn; 2023 Oct; 50(5):365-376. PubMed ID: 37344637
    [Abstract] [Full Text] [Related]

  • 7. Systematic Development and Verification of a Physiologically Based Pharmacokinetic Model of Rivaroxaban.
    Cheong EJY, Teo DWX, Chua DXY, Chan ECY.
    Drug Metab Dispos; 2019 Nov; 47(11):1291-1306. PubMed ID: 31506301
    [Abstract] [Full Text] [Related]

  • 8. Investigation of the arcane inhibition of human organic anion transporter 3 by benzofuran antiarrhythmic agents.
    Tan HL, Tang LWT, Chin SY, Chan ECY.
    Drug Metab Pharmacokinet; 2021 Jun; 38():100390. PubMed ID: 33836300
    [Abstract] [Full Text] [Related]

  • 9. Application of Static Modeling --in the Prediction of In Vivo Drug-Drug Interactions between Rivaroxaban and Antiarrhythmic Agents Based on In Vitro Inhibition Studies.
    Cheong EJ, Goh JJ, Hong Y, Venkatesan G, Liu Y, Chiu GN, Kojodjojo P, Chan EC.
    Drug Metab Dispos; 2017 Mar; 45(3):260-268. PubMed ID: 28053220
    [Abstract] [Full Text] [Related]

  • 10. Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects.
    Mueck W, Kubitza D, Becka M.
    Br J Clin Pharmacol; 2013 Sep; 76(3):455-66. PubMed ID: 23305158
    [Abstract] [Full Text] [Related]

  • 11. Physiologically-based pharmacokinetic modeling to predict drug-drug interactions of dabigatran etexilate and rivaroxaban in the Chinese older adults.
    Sia JEV, Lai X, Wu X, Zhang F, Li H, Cui C, Liu D.
    Eur J Pharm Sci; 2023 Mar 01; 182():106376. PubMed ID: 36626944
    [Abstract] [Full Text] [Related]

  • 12. Impact of P-glycoprotein and CYP3A4-interacting drugs on clinical outcomes in patients with atrial fibrillation using non-vitamin K antagonist oral anticoagulants: a nationwide cohort study.
    Grymonprez M, Carnoy L, Capiau A, Boussery K, Mehuys E, De Backer TL, Steurbaut S, Lahousse L.
    Eur Heart J Cardiovasc Pharmacother; 2023 Dec 14; 9(8):722-730. PubMed ID: 37791408
    [Abstract] [Full Text] [Related]

  • 13. Simultaneously predict pharmacokinetic interaction of rifampicin with oral versus intravenous substrates of cytochrome P450 3A/P‑glycoprotein to healthy human using a semi-physiologically based pharmacokinetic model involving both enzyme and transporter turnover.
    Qian CQ, Zhao KJ, Chen Y, Liu L, Liu XD.
    Eur J Pharm Sci; 2019 Jun 15; 134():194-204. PubMed ID: 31047967
    [Abstract] [Full Text] [Related]

  • 14. Unraveling pleiotropic effects of rifampicin by using physiologically based pharmacokinetic modeling: Assessing the induction magnitude of P-glycoprotein-cytochrome P450 3A4 dual substrates.
    Pan X, Yamazaki S, Neuhoff S, Zhang M, Pilla Reddy V.
    CPT Pharmacometrics Syst Pharmacol; 2021 Dec 15; 10(12):1485-1496. PubMed ID: 34729944
    [Abstract] [Full Text] [Related]

  • 15. Assessment of Anti-Xa activity in patients receiving concomitant apixaban with strong p-glycoprotein inhibitors and statins.
    Milner E, Ainsworth M, Gleaton M, Bookstaver D.
    J Clin Pharm Ther; 2022 May 15; 47(5):668-675. PubMed ID: 35032137
    [Abstract] [Full Text] [Related]

  • 16. Risk of Major Bleeding in Patients With Atrial Fibrillation Taking Dronedarone in Combination With a Direct Acting Oral Anticoagulant (From a U.S. Claims Database).
    Gandhi SK, Reiffel JA, Boiron R, Wieloch M.
    Am J Cardiol; 2021 Nov 15; 159():79-86. PubMed ID: 34656316
    [Abstract] [Full Text] [Related]

  • 17. Relevance of P-glycoprotein in stroke prevention with dabigatran, rivaroxaban, and apixaban.
    Stöllberger C, Finsterer J.
    Herz; 2015 Apr 15; 40 Suppl 2():140-5. PubMed ID: 25616425
    [Abstract] [Full Text] [Related]

  • 18. Clinical significance of the rivaroxaban-dronedarone interaction: insights from physiologically based pharmacokinetic modelling.
    Hügl B, Horlitz M, Fischer K, Kreutz R.
    Eur Heart J Open; 2023 Jan 15; 3(1):oead004. PubMed ID: 36820238
    [Abstract] [Full Text] [Related]

  • 19. Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin.
    Gouin-Thibault I, Delavenne X, Blanchard A, Siguret V, Salem JE, Narjoz C, Gaussem P, Beaune P, Funck-Brentano C, Azizi M, Mismetti P, Loriot MA.
    J Thromb Haemost; 2017 Feb 15; 15(2):273-283. PubMed ID: 27893182
    [Abstract] [Full Text] [Related]

  • 20. Clinical pharmacology of dronedarone: implications for the therapy of atrial fibrillation.
    Dorian P.
    J Cardiovasc Pharmacol Ther; 2010 Dec 15; 15(4 Suppl):15S-8S. PubMed ID: 20472816
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.